Haval Shirwan, Ph.D.
Intro | Research Interests | Biosketch | Selected Publications | Staff | Positions Available

PATENTS ISSUED

PUBLICATIONS

Schabowsky R-H, Sharma RK, Madireddi S, Srivastava A, Yolcu ES, Shirwan H

ProtEx™ technology for the generation of novel therapeutic cancer vaccines

Exp Mol Path June 2009 June;86 (3):139-234.

http://www.ncbi.nlm.nih.gov/pubmed/19454266

Sharma RK, Elpek GK, Yolcu ES, Schabowsky R-H, Zhao H, Bandura-Morgan L, Shirwan H

Costimulation as a Platform for the Development of Vaccines: A Peptide-Based Vaccine Containing a Novel form of 4-1BB Ligand Eradicates Established Tumors

Cancer Res 2009 May;69:(10), In press.

http://www.ncbi.nlm.nih.gov/pubmed/19435920

Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H.

Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein.

J Immunol. 2008 Jul 15;181(2):931-9.

http://www.ncbi.nlm.nih.gov/pubmed/18606644

Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H.

Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.

Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8.

http://www.ncbi.nlm.nih.gov/pubmed/18058571

Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H.

Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.

J Immunol. 2007 Dec 1;179(11):7295-304.

http://www.ncbi.nlm.nih.gov/pubmed/18025172

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Shirwan H, Yaniv I, Askenasy N.

Expression of Fas and Fas-ligand in donor hematopoietic stem and progenitor cells is dissociated from the sensitivity to apoptosis.

Exp Hematol. 2007 Oct;35(10):1601-12.

http://www.ncbi.nlm.nih.gov/pubmed/17889725

Pearl-Yafe M, Stein J, Yolcu ES, Farkas DL, Shirwan H, Yaniv I, Askenasy N.

Fas transduces dual apoptotic and trophic signals in hematopoietic progenitors.

Stem Cells. 2007 Dec;25(12):3194-203. Epub 2007 Sep 13.

http://www.ncbi.nlm.nih.gov/pubmed/17872500

Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H.

CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.

J Immunol. 2007 Jun 1;178(11):6840-8.

http://www.ncbi.nlm.nih.gov/pubmed/17513732

Pearl-Yafe M, Yolcu ES, Stein J, Kaplan O, Yaniv I, Shirwan H, Askenasy N.

Fas ligand enhances hematopoietic cell engraftment through abrogation of alloimmune responses and nonimmunogenic interactions.

Stem Cells. 2007 Jun;25(6):1448-55. Epub 2007 Mar 15.

http://www.ncbi.nlm.nih.gov/pubmed/17363551

Franke DD, Yolcu ES, Alard P, Kosiewicz MM, Shirwan H.

A novel multimeric form of FasL modulates the ability of diabetogenic T cells to mediate type 1 diabetes in an adoptive transfer model.

Mol Immunol. 2007 Apr;44(11):2884-92. Epub 2007 Feb 26.

http://www.ncbi.nlm.nih.gov/pubmed/17324464

Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, Shirwan H, Sam Zhou H, McMasters KM.

Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.

Cancer Immunol Immunother. 2007 Jul;56(7):997-1007. Epub 2006 Dec 5.

http://www.ncbi.nlm.nih.gov/pubmed/17146630

Singh NP, Miller RW, Yolcu ES, Kilinc MO, Oechsli M, Huseby R, Taylor DD, Perry MT, Larocca RV, Shirwan H.

Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo.

Hum Gene Ther. 2006 Mar;17(3):334-46.

http://www.ncbi.nlm.nih.gov/pubmed/16544982

Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H.

Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon.

Exp Mol Pathol. 2006 Jun;80(3):252-61. Epub 2006 Feb 17.

http://www.ncbi.nlm.nih.gov/pubmed/16487512

Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N.

The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation.

Bioessays. 2006 Feb;28(2):211-22.

http://www.ncbi.nlm.nih.gov/pubmed/16435302

Franke DD, Shirwan H.

Prophylactic fenbendazole therapy does not affect the incidence and onset of type 1 diabetes in non-obese diabetic mice.

Int Immunol. 2006 Mar;18(3):453-8. Epub 2006 Jan 13.

http://www.ncbi.nlm.nih.gov/pubmed/16415097

Singh NP, Yolcu ES, Askenasy N, Shirwan H.

ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.

Ann N Y Acad Sci. 2005 Nov;1056:344-58.

http://www.ncbi.nlm.nih.gov/pubmed/16387700

Köksoy S, Elpek KG, Yolcu ES, Shirwan H.

Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+CD25+ Treg cells.

Transplantation. 2005 Jun 15;79(11):1492-7.

http://www.ncbi.nlm.nih.gov/pubmed/15940037

Askenasy N, Yolcu ES, Yaniv I, Shirwan H.

Induction of tolerance using Fas ligand: a double-edged immunomodulator.

Blood. 2005 Feb 15;105(4):1396-404. Epub 2004 Oct 14. Review.

http://www.ncbi.nlm.nih.gov/pubmed/15486063

Köksoy S, Kakoulidis TP, Shirwan H.

Chronic heart allograft rejection in rats demonstrates a dynamic interplay between IFN-gamma and IL-10 producing T cells.

Transpl Immunol. 2004 Nov;13(3):201-9.

http://www.ncbi.nlm.nih.gov/pubmed/15381203

Singh NP, Guo L, Que X, Shirwan H.

Blockade of indirect recognition mediated by CD4+ T cells leads to prolonged cardiac xenograft survival.

Xenotransplantation. 2004 Jan;11(1):33-42.

http://www.ncbi.nlm.nih.gov/pubmed/14962291

Askenasy N, Yolcu ES, Shirwan H, Stein J, Yaniv I, Farkas DL.

Characterization of adhesion and viability of early seeding hematopoietic cells in the host bone marrow in vivo and in situ.

Exp Hematol. 2003 Dec;31(12):1292-300.

http://www.ncbi.nlm.nih.gov/pubmed/14662337

Singh NP, Yolcu ES, Taylor DD, Gercel-Taylor C, Metzinger DS, Dreisbach SK, Shirwan H.

A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity.

Cancer Res. 2003 Jul 15;63(14):4067-73.

http://www.ncbi.nlm.nih.gov/pubmed/12874008

Shirwan H, Mhoyan A, Yolcu ES, Que X, Ibrahim S.

Chronic cardiac allograft rejection in a rat model disparate for one single class I MHC molecule is associated with indirect recognition by CD4(+) T cells.

Transpl Immunol. 2003 Apr-Jun;11(2):179-85.

http://www.ncbi.nlm.nih.gov/pubmed/12799202

Shirwan H, Mhoyan A, Kakoulidis TP, Yolcu ES, Ibrahim S.

Prevention of chronic rejection with immunoregulatory cells induced by intrathymic immune modulation with class I allopeptides.

Am J Transplant. 2003 May;3(5):581-9.

http://www.ncbi.nlm.nih.gov/pubmed/12752314

Mhoyan A, Wu GD, Kakoulidis TP, Que X, Yolcu ES, Cramer DV, Shirwan H.

Predominant expression of the Th2 response in chronic cardiac allograft rejection.

Transpl Int. 2003 Aug;16(8):464-73. Epub 2003 Apr 24.

http://www.ncbi.nlm.nih.gov/pubmed/12712237

Askenasy N, Yolcu ES, Wang Z, Shirwan H.

Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.

Circulation. 2003 Mar 25;107(11):1525-31.

http://www.ncbi.nlm.nih.gov/pubmed/12654611

Singh NP, Guo L, Mhoyan A, Shirwan H.

Predominant expression of Th2 cytokines and interferon-gamma in xenogeneic cardiac grafts undergoing acute vascular rejection.

Transplantation. 2003 Mar 15;75(5):586-90.

http://www.ncbi.nlm.nih.gov/pubmed/12640294

Askenasy N, Yolcu ES, Shirwan H, Wang Z, Farkas DL.

Cardiac allograft acceptance after localized bone marrow transplantation by isolated limb perfusion in nonmyeloablated recipients.

Stem Cells. 2003;21(2):200-7

http://www.ncbi.nlm.nih.gov/pubmed/12634416

Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H.

Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection.

Immunity. 2002 Dec;17(6):795-808.

http://www.ncbi.nlm.nih.gov/pubmed/12479825

Science from Bench to Bedside